JT Stratford LLC Buys 22,929 Shares of Bristol-Myers Squibb (NYSE:BMY)

JT Stratford LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 215.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,554 shares of the biopharmaceutical company's stock after acquiring an additional 22,929 shares during the period. JT Stratford LLC's holdings in Bristol-Myers Squibb were worth $1,898,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb by 9.4% in the fourth quarter. Ameritas Advisory Services LLC now owns 15,807 shares of the biopharmaceutical company's stock valued at $894,000 after purchasing an additional 1,357 shares during the period. Diversify Wealth Management LLC increased its holdings in shares of Bristol-Myers Squibb by 10.0% in the fourth quarter. Diversify Wealth Management LLC now owns 14,123 shares of the biopharmaceutical company's stock valued at $788,000 after purchasing an additional 1,286 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Bristol-Myers Squibb by 4.0% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 8,687 shares of the biopharmaceutical company's stock valued at $491,000 after purchasing an additional 332 shares during the period. LaFleur & Godfrey LLC boosted its stake in shares of Bristol-Myers Squibb by 3.5% in the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after buying an additional 1,487 shares during the last quarter. Finally, Pure Financial Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 48.2% in the fourth quarter. Pure Financial Advisors LLC now owns 7,808 shares of the biopharmaceutical company's stock worth $442,000 after buying an additional 2,538 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Jefferies Financial Group lowered their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Piper Sandler initiated coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Finally, Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Activity

In other news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. This represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.07% of the company's stock.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $46.97 on Thursday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market cap of $95.58 billion, a PE ratio of -10.63, a P/E/G ratio of 2.07 and a beta of 0.39. The stock has a 50 day moving average price of $52.31 and a 200 day moving average price of $55.83.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($4.40) earnings per share. Equities research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.28%. Bristol-Myers Squibb's payout ratio is presently 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.